- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.08. | Aquestive signs $75m agreement for launch of Anaphylm | ||
| 18.08. | Sanofi receives orphan status from EMA for rilzabrutinib | ||
| 18.08. | Addressing inefficiencies in clinical trial data management | ||
| 18.08. | FDA approves Tonix's Tonmya to treat fibromyalgia | ||
| 15.08. | Sanofi's Tzield secures MHRA go-ahead for type 1 diabetes | ||
| 15.08. | Trump targets bolstering of US emergency drug reserve | ||
| 15.08. | UK pharmacist says Eli Lilly's Mounjaro price hike a "shock" | ||
| 15.08. | Infectious disease screening during substance use disorder treatment increases detection, prevention, and treatment | ||
| 15.08. | AI is improving idiopathic pulmonary fibrosis care | ||
| 15.08. | CDMO insights podcast series: Our Experience is Your Strength | Episode #4 Commercial Launch | ||
| 14.08. | UK chikungunya cases rise amid vaccine safety concerns | ||
| 14.08. | US eosinophilic oesophagitis market to reach $1.19bn by 2030 | ||
| 14.08. | Basilea secures rights to Venatorx's antibiotic for complicated UTIs | ||
| 14.08. | Apertura signs multiple licensing agreements for TfR1 CapX tech | ||
| 13.08. | Eli Lilly accused of bribing providers to prescribe GLP-1RA drugs | ||
| 13.08. | Insmed wins FDA approval for future blockbuster Brinsupri | ||
| 13.08. | PureTech forms respiratory spin-off Celea to advance deuterated pirfenidone | ||
| 13.08. | Amphastar and Anji make licence agreement for three new peptides | ||
| 13.08. | How to solve the big challenges of cell and gene therapy manufacturing | ||
| 13.08. | A new way forward in ovarian cancer: why synthetic iMSCs could change the paradigm | ||
| 13.08. | AbbVie expands North Chicago API production with $195m investment | ||
| 12.08. | Podcast: US tariff news and Q2 earnings influence pharma trends | ||
| 12.08. | Eli Lilly and GSK drive South Korea's drug licensing activity | ||
| 12.08. | Third time lucky as PharmaTher gets FDA approval for ketamine | ||
| 12.08. | Prasad's shock FDA return reignites regulatory uncertainty |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .